Donepezil (Aricept) for Alzheimer's Disease
Donepezil hydrochloride (Aricept - Eisai), a piperidine-based acetylcholinesterase inhibitor, is now being marketed for oral treatment of cognitive symptoms in patients with mild to moderate dementia due to Alzheimer's disease. Donepezil is the second drug approved for this indication; tacrine hydrochloride (Cognex), also an acetylcholinesterase inhibitor, has been available in the USA for four years (Medical Letter, 35:87, 1993)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Donepezil (Aricept) for Alzheimer's Disease
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1002
Article Code: 1002a
Date: June 6, 1997
Volume: 39
Pages: 53-54
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1002
Article Code: 1002a
Date: June 6, 1997
Volume: 39
Pages: 53-54
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)